Here are three things to know.
- Abilify Maintena is a once-daily injectable antipsychotic drug for intramuscular use.
- The agency first approved the drug in 2013 to treat schizophrenia.
- Abilify Maintena may now be used as a monotherapy for adults with bipolar I disorder.
More articles on supply chain:
Merck warns of drug delays after ‘NotPetya’ cyberattack: 3 things to know
6 must-reads for supply chain leaders this week
Drug packager recalls muscle spasm, Parkinson’s drugs over labeling errors
